课题基金 / 基金详情

Administrative Core

Administrative Core
行政核心
批准号:
10262915
负责人:
Christopher K Glass
金额:
$12.54万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-21 至 2025-07-31

项目摘要

项目成果

Christopher K Glass的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 核心C:行政核心 建议设立一个行政核心,以支持计划项目赠款的行政需求。主要 核心的职能是提供决策结构,定期组织项目规划小组会议, 内部和外部咨询和审查机制,以及有效利用资源。这一核心将是 由Drs. Glass和Witztum共同执导。Glass博士、Witztum博士、Evans博士、Loomba博士和Benner博士( 项目1、3、2和核心B)将组成执行委员会进行日常决策。一个 由Nicholas Schork博士、Alan Saltiel博士和Tatiana Kisseleva博士组成的内部咨询委员会将 提供行政和科学咨询。将成立一个外部咨询小组, 每年的科学计划。将选择外部咨询小组,以包括NASH方面的专业知识, 动脉粥样硬化、炎症、基因表达和统计学。行政核心将负责 确保PPG符合资源共享计划、模式生物和数据共享 分享计划。行政核心还将负责编制年度非竞争性 退款
英文摘要
PROJECT SUMMARY Core C: Administrative core An Administrative Core is proposed to support the administrative needs of the Program Project Grant. The major functions of the Core will be to provide a structure for decision making, organization of regular PPG meetings, mechanisms for internal and external advice and review, and effective utilization of resources. This Core will be Co-Directed by Drs. Glass and Witztum. Dr. Glass, Dr. Witztum, Dr. Evans, Dr. Loomba and Dr. Benner (PIs of Projects 1, 3, 2, and Core B respectively) will form an executive committee for routine decision making. An internal advisory committee consisting of Dr. Nicholas Schork, Dr. Alan Saltiel and Dr. Tatiana Kisseleva will provide both administrative and scientific advice. An external advisory group will be constituted to review the scientific program on an annual basis. The external advisory group will be selected to include expertise in NASH, atherosclerosis, inflammation, gene expression and statistics. The Administrative Core will be responsible for ensuring that the PPG conforms to the Resource Sharing Plan, the Sharing of Model Organisms and the Data Sharing Plan. The Administrative Core will also be responsible for preparation of the Annual Non Competing renewal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?
Macrophage-specific targeting of LXRs in CVD and NASH
A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?
Macrophage-specific targeting of LXRs in CVD and NASH
海外基金